neck

BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers.

Pulrodemstat (CC-90011) is an orally active, selective, and highly efficient lysine-specific demethylase-1 (LSD1) inhibitor with anticancer activity. It inhibits HNSCC cell proliferation and migration by triggering apoptosis and inhibiting head and neck squamous cell carcinoma growth.

Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).

Pulrodemstat HCl is an orally active, selective and potent lysine demethylase-1 (LSD1) inhibitor, and a selective KDM1A inhibitor, with anticancer and anti-proliferative activities, inhibiting HNSCC cell proliferation and migration Inhibits the growth of head and neck squamous cell carcinoma by triggering apoptosis.

Luminespib (VER-52296) is an HSP90 inhibitor that inhibits HSP90α and HSP90β (IC50=7.8 21 nM). Luminespib has antitumor activity and is used in studies of head and neck tumors, among others.

LGK974 (NVP-LGK974) is an effective and selective PORCN inhibitor and inhibits Wnt signaling (IC50: 0.4 nM) in TM3 cells. It has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.

NCGC00262650 is an inhibitor of AMA1-RON2 interaction and c-Src tyrosine kinase activity.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH). It treats difficulty urinating, a common symptom of an enlarged prostate, by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, easing urination.

Temoporfin used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck.

Borofalan (also known as SPM 011) is an adjuvant compound used in boron neutron capture therapy (BNCT) for cancer treatment. BNCT leverages the high neutron capture cross-section of boron-containing compounds (10 B) and facilitates the 10 B(n,α) 7 Li neutron capture and nuclear fission reaction. With the use of borofalan (10B)-containing C-BENS, BNCT has demonstrated effective therapeutic potential in patients with R-SCC or R LA-nSCC of the head and neck. Note: We offer the non-labeled version of Borofalan.

PROTAC LZK-IN-1 (Compound 21A) is a PROTAC molecule that targets the degradation of LZK (leucine zipper kinase, encoded by MAP3K13). At a concentration of 10 μM, PROTAC LZK-IN-1 facilitates the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. This compound is applicable in anticancer research.

Wntpathway inhibitor 5 (Compound 28) is an effective wntpathway inhibitor with an IC50 value of less than 0.003 μM. This compound can suppress various types of cancers such as ovarian teratoma, breast cancer, osteosarcoma, and head and neck squamous cell carcinoma.

Antitumor agent-198 (Compound A3) exhibits cytotoxicity in head and neck squamous cell carcinoma (HNSCC) cells, effectively inhibiting the proliferation of CAL27, HN6, HN30, SCC9, and SCC25, with an IC50 ranging from 4 nM to 77 nM. Additionally, Antitumor agent-198 suppresses HNSCC cell migration, arrests the cell cycle, and induces apoptosis.

Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.

Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).

Amethopterin is a chemotherapy drug and immune system inhibitor used to treat cancers of the blood, bone, lung, breast, head, and neck. In addition, it can treat rheumatoid arthritis and psoriasis.

C24 dihydro Ceramide is a sphingolipid that has been found in the stratum corneum of human skin.[1] It is found in higher concentrations in female sebum compared to male sebum.[2] C24 dihydro Ceramide levels positively correlate with cytotoxicity in CCRF-CEM, MOLT-4, COG-LL-317h, and COG-LL-332h T cell acute lymphoblastic leukemia (ALL) cell lines.[4] Levels of C24 dihydro ceramide are increased by 149.49-fold in dihydroceramide desaturase 1 (DEGS1) knockdown UM-SCC-22A human head and neck squamous carcinoma cells in vitro.[4] C24 dihydro Ceramide levels are also increased in INS-1 β-cells incubated with glucose and palmitate.[5]

JH-XIV-68-3 is a selective inhibitor of the DYRK1A B macrocycle, acting specifically on DYRK1A and DYRK1B in biochemical and cellular assays, and exhibiting antitumor effects in head and neck squamous cell carcinoma (HNSCC) cell lines.

JH-XVII-10 is a selective, orally active and potent inhibitor of DYRK1A (IC50: 3 nM) and DYRK1B (IC50: 5 nM).JH-XVII-10 exhibits antitumor effects in squamous cell carcinoma of the neck (HNSCC) cell lines.

EGFR-IN-59 is an EGFR inhibitor with an IC50 value of 190 nM and an all-time apoptosis inducer. EGFR-IN-59 exhibited cytotoxicity against a non-small lung cancer cell line (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 μM, respectively. EGFR-IN-59 EGFR-IN-59 can be used to study a variety of cancers including non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer.

Edatrexate (CGP 30694), also known as 10-Ethyl-10-deazaaminopterin, is an analog of Methotrexate that demonstrates antitumor activity against Methotrexate-resistant tumors. This antifolate antimetabolite is utilized in research related to non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and head and neck cancer [1] [2].

PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.

NR2F1 agonist 1, a specific nuclear receptor NR2F1 activator, initiates dormancy programs in cancer cells by upregulating NR2F1 and its target genes controlling dormancy. This compound promotes neural crest-like features and suppresses growth in head and neck squamous cell carcinoma (HNSCC) through NR2F1 activation. Moreover, NR2F1 agonist 1 demonstrates tumor growth inhibition in a mouse primary tumor model.

Botulinum toxin type B, an antigen-specific exotoxin produced by the anaerobic bacterium Clostridium botulinum, is utilized in the study of neck dystonia. It inhibits the release of Acetylcholine from the neuromuscular junction, causing relaxation paralysis or muscle weakening in the targeted muscle [1].